Management of antiretroviral therapy in HIV-infected patients exhibiting virological failure;Gestion du traitement antirétroviral chez les patients infectés par le VIH, en échec thérapeutique

Presse Medicale

Volumn 31, Issue 22, 2002, Pages 1034-1040

  Pinganaud, C ^a   Goujard, Cécile ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG CHOICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFECTION RESISTANCE; PATIENT COMPLIANCE; PATIENT MONITORING; PRESCRIPTION; REVIEW; TREATMENT FAILURE; VIRUS DETECTION;

ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE; HIV INFECTIONS; HUMANS; NUTRITIONAL STATUS; PATIENT COMPLIANCE; PROGNOSIS; VIRAL LOAD;

EID: 0037157548     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Plasma viral load and CD4 + lymphocytes as prognostic markers of HIV-1 infection
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
3. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection
4. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease
5. Clinical outcome of patients with HIV-1 infection according to immunological and virological response after 6 months of highly active antiretroviral therapy
6. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-terme response to therapy
7. Traitement artirétroviral
8. Latent infection of CD4 + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
9. Maintenance antiretroviral therapy in HIV-infected patients with undectable plasma HIV RNA after triple-drug therapy
10. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
11. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
12. CD4-cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)
13. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
14. Highly active antiretroviral therapy in a large urban clinic
15. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population
16. Virological and immunological characteristics of HIV treatment failure
17. The virological reponse to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4-8 viral load
18. Sustained CD4 + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
19. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection
20. Predictors of optimal virological response to potent antiretroviral therapy
21. CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1 infected patients
22. Virological and immunological response to HAART therapy in a community-based cohort of HIV-1 positive individuals
23. CD4 cell counts at the third month of HAART may predict clinical failure
24. The use of and response to second-line protease inhibitor regimens: Results from the EusoSIDA study
25. The Atlantic study: A randomized, open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48 week data
26. Abacavir-lamivudine-zidovudine versus indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial
27. HIV drug resistance and insufficient drug plasma levels as factors determining antiretroviral treatment failure
28. Adherence to triple therapy and viral load response
29. Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment
30. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
31. Resistance aux antirétroviraux
32. Résistance du VIH aux antirétroviraux
33. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients
34. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients patients with failure of highly active antiretroviral therapy
35. Resistance-associated loss of viral fitness in human immunodeficiency, virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
36. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro
37. High levels of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4 + T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy
38. Altered viral fitness of HIV-1 following failure of therapy
39. Resistance, fitness, adherence, and potency
40. HIV treatment failure: Testing for HIV resistance in clinical practice
41. HIV-specific immune responses in subjects with high level viral suppression with or without intermittent viremia treated for 3-5 years with HAART
42. Low-level HIV viral rebound and blips in patients receiving potent antiretroviral therapy
43. Tests de resistance aux antirétroviraux
44. Impact of treatment guided by phenotypic or genotypic resistance test on the response to antiretroviral therapy: A randomized trial (Narval, ANRS 088)
45. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine
46. Infection by ziduvodine HIV-1 compromises the virological response to stavudine in a drug-naive patient
47. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
48. Les traitements antirétroviraux. Bilan des stratégies et indications thérapeutiques
49. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens
50. Changes in CD4 lymphocytes counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens
51. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure
52. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
53. Gighaart (ANRS 297): A prospective randomized trial comparing the efficacity of a salvage regimen administrated with or without treatment interruption in patients with severe biological failure and extensive prior therapy
54. The case for more cautious, patient-focused antiretroviral therapy
55. Antiretroviral therapy: Time to think strategically
56. Should physicians withhold highly active antiretroviral therapies from HIV-AIDS patients who are thought to be poorly adherent to treatment?
57. Reassessing the goal of antiretroviral therapy in the heavily pre-treated HIV-infected patient